View in EDS HTML Full Text PDF Full Text

A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.

Saved in:
Bibliographic Details
Title: A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
Authors: Saif MW; Medical Oncology, Northwell Health Cancer Institute, 1111 Marcus Avenue, Suite 216, Lake Success, NY, 11042, USA. wsaif@northwell.edu., Becerra CR; Texas Oncology, Baylor University Medical Center, Dallas, TX, USA., Fakih MG; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Sun W; Division of Oncology, University of Kansas Medical Center, Kansas City, KS, USA., Popovic L; Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad, Serbia., Krishnamurthi S; Cleveland Clinic, Cleveland, OH, USA., George TJ; University of Florida Health Cancer Center, Gainesville, FL, USA., Rudek MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Shepard DR; Cleveland Clinic, Cleveland, OH, USA., Skopek J; Thomayer Hospital Prague and Department of Biophysics and Informatics, First Medical Faculty, Prague, Czech Republic., Sramek V; Fakultni Nemocnice u Sv. Anny v Brně, Anesteziologicko Resustitační Klinika, Brno, Czech Republic., Zaric B; Institute for Pulmonary Diseases of Vojvodina, University of Novi Sad, Novi Sad, Serbia., Yamamiya I; Taiho Oncology, Inc., Princeton, NJ, USA., Benhadji KA; Taiho Oncology, Inc., Princeton, NJ, USA., Hamada K; Taiho Oncology, Inc., Princeton, NJ, USA., He Y; Taiho Oncology, Inc., Princeton, NJ, USA., Rosen L; Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Sep; Vol. 88 (3), pp. 485-497. Date of Electronic Publication: 2021 Jun 07.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34097100
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Saif+MW%22">Saif MW</searchLink>; Medical Oncology, Northwell Health Cancer Institute, 1111 Marcus Avenue, Suite 216, Lake Success, NY, 11042, USA. wsaif@northwell.edu.<br /><searchLink fieldCode="AU" term="%22Becerra+CR%22">Becerra CR</searchLink>; Texas Oncology, Baylor University Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Fakih+MG%22">Fakih MG</searchLink>; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sun+W%22">Sun W</searchLink>; Division of Oncology, University of Kansas Medical Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Popovic+L%22">Popovic L</searchLink>; Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad, Serbia.<br /><searchLink fieldCode="AU" term="%22Krishnamurthi+S%22">Krishnamurthi S</searchLink>; Cleveland Clinic, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22George+TJ%22">George TJ</searchLink>; University of Florida Health Cancer Center, Gainesville, FL, USA.<br /><searchLink fieldCode="AU" term="%22Rudek+MA%22">Rudek MA</searchLink>; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Shepard+DR%22">Shepard DR</searchLink>; Cleveland Clinic, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22Skopek+J%22">Skopek J</searchLink>; Thomayer Hospital Prague and Department of Biophysics and Informatics, First Medical Faculty, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Sramek+V%22">Sramek V</searchLink>; Fakultni Nemocnice u Sv. Anny v Brně, Anesteziologicko Resustitační Klinika, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Zaric+B%22">Zaric B</searchLink>; Institute for Pulmonary Diseases of Vojvodina, University of Novi Sad, Novi Sad, Serbia.<br /><searchLink fieldCode="AU" term="%22Yamamiya+I%22">Yamamiya I</searchLink>; Taiho Oncology, Inc., Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Benhadji+KA%22">Benhadji KA</searchLink>; Taiho Oncology, Inc., Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Hamada+K%22">Hamada K</searchLink>; Taiho Oncology, Inc., Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22He+Y%22">He Y</searchLink>; Taiho Oncology, Inc., Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Rosen+L%22">Rosen L</searchLink>; Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227806519%22">Cancer chemotherapy and pharmacology</searchLink> [Cancer Chemother Pharmacol] 2021 Sep; Vol. 88 (3), pp. 485-497. <i>Date of Electronic Publication: </i>2021 Jun 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>7806519 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0843 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203445704%22">03445704 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Chemother Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34097100
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00280-021-04308-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 485
    Titles:
      – TitleFull: A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Saif MW
      – PersonEntity:
          Name:
            NameFull: Becerra CR
      – PersonEntity:
          Name:
            NameFull: Fakih MG
      – PersonEntity:
          Name:
            NameFull: Sun W
      – PersonEntity:
          Name:
            NameFull: Popovic L
      – PersonEntity:
          Name:
            NameFull: Krishnamurthi S
      – PersonEntity:
          Name:
            NameFull: George TJ
      – PersonEntity:
          Name:
            NameFull: Rudek MA
      – PersonEntity:
          Name:
            NameFull: Shepard DR
      – PersonEntity:
          Name:
            NameFull: Skopek J
      – PersonEntity:
          Name:
            NameFull: Sramek V
      – PersonEntity:
          Name:
            NameFull: Zaric B
      – PersonEntity:
          Name:
            NameFull: Yamamiya I
      – PersonEntity:
          Name:
            NameFull: Benhadji KA
      – PersonEntity:
          Name:
            NameFull: Hamada K
      – PersonEntity:
          Name:
            NameFull: He Y
      – PersonEntity:
          Name:
            NameFull: Rosen L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2021 Sep
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0843
          Numbering:
            – Type: volume
              Value: 88
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Cancer chemotherapy and pharmacology
              Type: main
ResultId 1